Angion and Elicio Therapeutics Enter Into Definitive Merger Agreement

Boston – January 19, 2023 – Cooley advised Angion, a clinical-stage biopharmaceutical company, on its definitive merger agreement with Elicio Therapeutics. Lawyers Kenneth Guernsey and Matthew Silverman led the Cooley team counseling Angion.

Elicio will merge with a wholly owned subsidiary of Angion in an all-stock transaction. The combined company will continue under the Elicio Therapeutics name and will focus on advancing Elicio’s proprietary lymph node-targeting amphiphile technology to develop immunotherapies, with a focus on ELI-002, a therapeutic cancer vaccine targeting mKRAS-driven tumors.

Angion has focused on the discovery, development and commercialization of novel small-molecule therapeutics to address fibrotic diseases.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has nearly 1,500 lawyers across 18 offices in the United States, Asia and Europe, and a total workforce of more than 3,000.